Molecularly Targeted Therapy May Improve Survival in Advanced, Recurrent Endometrial Cancer

Real-world data suggest that matched, targeted therapy may improve survival in patients with advanced or recurrent endometrial cancer.

Related Keywords

North Carolina ,United States ,Duke University Medical Center ,Roche Genentech ,Angeles Alvarez Secord ,Alvarez Secord ,Endometrial Cancer Molecularly Targeted Therapy Consortium ,National Cancer Trial Network ,Astrazeneca ,Cancer Therapy Advisor ,National Cancer Trial ,